• م.د.شهلاء زهير عبد المجيد
  • Shahlaa Zuhair Abdul-Majeed
  • تدريسي : كلية الصيدلة
  • Teaching : college of Pharmacy
  • صيدلانية/دكتوراه علوم الصيدلة-كيمياء صيدلانية
  • PhD in pharmacy science/pharmaceutical chemistry
  • shahla@esraa.edu.iq
  • pha.sha91@gmail.com
  • نشاطات التدريسي

    نشاطات التدريسي

    •	Passing the training
    م.د.شهلاء زهير عبد المجيد

    • Passing the training

    •	Actively participated in the third scientific symposium
    م.د.شهلاء زهير عبد المجيد

    • Actively participated in the third scientific symposium

    •	Passing the training
    م.د.شهلاء زهير عبد المجيد

    • Passing the training

    المقررات المكلف بها

    المقررات المكلف بها

    المقررات المكلف بها - 4
    القسم المرحلة الفصل رمز المقرر الوحدات توصيف المقرر
    كلية الصيدلة المرحلة الثالثة فصل اول IPC0930 3 Inorganic pharmaceutical chemistry
    كلية الصيدلة المرحلة الثالثة فصل ثاني OPC0931 4 Organic pharmaceutical chemistry I
    كلية الصيدلة المرحلة الخامسة فصل ثاني APA0950 4 Advanced pharmaceutical analysis
    كلية الصيدلة المرحلة الخامسة فصل ثاني 4 Advanced pharmaceutical analysis laboratory
    المحاضرات الالكترونية

    المحاضرات الالكترونية

    المحاضرات الالكترونية - 16
    العام المقرر القسم المرحلة المحاضرة
    2022-2023 Advanced pharmaceutical analysis laboratory كلية الصيدلة المرحلة الخامسة Introduction &demonstration to visible spectrophotometry
    2022-2023 Organic pharmaceutical chemistry I كلية الصيدلة المرحلة الثالثة Pathways of biotransformation
    2022-2023 Organic pharmaceutical chemistry I كلية الصيدلة المرحلة الثالثة Site of drug biotransformation
    2022-2023 Organic pharmaceutical chemistry I كلية الصيدلة المرحلة الثالثة Drug biotransformation and metabolic changes of drugs
    2022-2023 Organic pharmaceutical chemistry I كلية الصيدلة المرحلة الثالثة Acidity and basicity
    2022-2023 Organic pharmaceutical chemistry I كلية الصيدلة المرحلة الثالثة Physicochemical Properties
    2022-2023 Organic pharmaceutical chemistry I كلية الصيدلة المرحلة الثالثة Introduction to Medicinal Chemistry
    2022-2023 Inorganic pharmaceutical chemistry كلية الصيدلة المرحلة الثالثة Radio pharmaceutics
    2022-2023 Inorganic pharmaceutical chemistry كلية الصيدلة المرحلة الثالثة Topical agents
    2022-2023 Inorganic pharmaceutical chemistry كلية الصيدلة المرحلة الثالثة Protectives-adsorbents & Cathartics
    2022-2023 Inorganic pharmaceutical chemistry كلية الصيدلة المرحلة الثالثة Antacid
    2022-2023 Inorganic pharmaceutical chemistry كلية الصيدلة المرحلة الثالثة Gastrointestinal Agents: acidifying agents
    2022-2023 Inorganic pharmaceutical chemistry كلية الصيدلة المرحلة الثالثة Essential and trace ions
    2022-2023 Inorganic pharmaceutical chemistry كلية الصيدلة المرحلة الثالثة Non-Essential Ions
    2022-2023 Inorganic pharmaceutical chemistry كلية الصيدلة المرحلة الثالثة Coordination /complexation
    2022-2023 Inorganic pharmaceutical chemistry كلية الصيدلة المرحلة الثالثة Atomic and molecular structure/complexation
    البحوث

    البحوث

    2023 Al Mustansiriyah Journal of Pharmaceutical Sciences

    A series of nine novel 4, 5-dihydro-1H- pyrazole-1-yl acetate derivatives (IVa-i) by Shahlaa et al. was investigated in vitro for their antiproliferative activity against two cancer cell lines, breast cancer cell line (MCF-7) and lung cancer cell lines (A549), According to the cytotoxicity effect of these compounds, IVa, IVc and IVi compounds have antiproliferative effect with percentage (81.30%, 87.4% & 54.66%) respectively at 72h treatment on MCF-7 cell line compared to other compounds, these results indicate that the new compound IVc have the higher antiproliferative percent comparable to tamoxifen as a standard anti-tumour for oestrogen receptor positive breast cancer cell line after 72h followed by IVa after 72h (83.31%). cytotoxicity effect of compound IVb was highest among tested compounds on lung cancer cell line (A549) with antiproliferative percentage (58.49% & 75.04%) at 48 & 72h respectively, but it is less than erlotinib as a standard anti-tumour for lung cancer cell line cytotoxicity effect (77.10% & 82.46%) at these times. three compounds (IVa, IVc & IVi) have antiproliferative effect on breast cancerous cell line (MCF-7) and compound (IVc) have inhibition percentage comparable to that of the authorized medication Tamoxifen. One compound (IVb) had antiproliferative activity, but less than that of erlotinib on lung cancerous cell line (A549) and there is good agreement between our docking results and the experimental results.

    2022 International Journal of Drug Delivery Technology

    A series of nine novel 4, 5-dihydro-1H- pyrazole-1-yl acetate derivatives (IVa-i) by Shahla et al. were investigated in-vitro fortheir ability to prohibit arachidonic acid (AA) from becoming prostaglandin H2 (PGH2), the inhibitory effects were foundat 0.016 and 0.02 nM for compounds IVe and IVf, respectively, this was due to high affinity for binding with cyclooxygenase(COX) enzymes. kinetics study and binding affinity results of these compounds showed good Kd constant of IVe and IVf withCOX at (0.008 and 0.003 nM), respectively. Cytotoxicity of these two compounds in RAW 264.7 macrophages cell lines wereperformed for anti-inflammatory testing, determine their non-cytotoxic concentration to make sure that their anti-inflammatoryactivity not caused by cytotoxicity, results showed that IVe (IC50 = 4.2 μM) and IVf (IC50 = 2.7 μM), respectively. CompoundIVe decreased the COX fold activity followed by compound IVf more than the positive control at the same concentration.During the evaluation of pro-inflammatory marker nitric oxide (NO) level with these compounds, results showed that the levelsignificantly reduced in the presence of IVe & IVf at (5 and 10 μM) and (2.5 and 5 μM) respectively. Determination the levelof cytokines with these compounds also performed, compounds IVe at concentration of (10 μM) and IVf (5 μM) significantlyreduced the mean level of TNF-α. Significant reduction of proinflammatory IL-1β and IL-6 mean level production was observedat 10 μM of compound IVe and 2.5, 5 μM of compound IVf. The results showed good indication for the anti-inflammatoryactivity of these compounds and to optimize activity, further structural optimization is required. in the future study.
    (4) (PDF) Pharmacological Evaluation of New 4, 5-dihydro-1H- Pyrazole-1-yl acetate Derivatives as Anti-inflammatory Agents. Available from:
    https://www.researchgate.net/publication/367328189_Pharmacological_Evaluation_of_New_4_5-dihydro-1H-_Pyrazole-1-yl_acetate_Derivatives_as_Anti-inflammatory_Agents [accessed Sep 02 2023].

    المؤلفات

    المؤلفات

    2022 Iraq